CSF or Serum Neurofilament Light Added to α‐Synuclein Panel Discriminates Parkinson's From Controls. Issue 2 (18th November 2019)

• Record Type: Journal Article
• Authors: Oosterveld, Linda P.; Verberk, Inge M.W.; Majbour, Nour K.; El‐Agnaf, Omar M.; Weinstein, Henry C.; Berendse, Henk W.; Teunissen, Charlotte E.; van de Berg, Wilma D.J.
• Is Part Of: Movement disorders. Volume 35:Issue 2(2020)
• Page Start: 288
• Page End: 295
• Publication Date: 2019-11-18
• Subjects: CSF biomarkers -- neurofilament light -- Parkinson's disease -- serum biomarkers; Movement disorders -- Periodicals; 610
• DOI: 10.1002/mds.27897
• Languages: English
• ISSNs: 0885-3185

Abstract

Abstract: Background: Neurofilament light chain is a marker of axonal damage and is of interest as a biofluid biomarker for PD. The objective of this study was to investigate whether CSF or serum neurofilament contributes to a combination of CSF biomarkers in defining the optimal biomarker panel for discriminating PD patients from healthy controls. In addition, we aimed to assess whether CSF and/or serum neurofilament levels are associated with clinical measures of disease severity. Methods: We measured neurofilament light chain levels in CSF and/or serum of 139 PD patients and 52 age‐matched healthy controls. We used stepwise logistic regression analyses to test whether neurofilament contributes to a biomarker CSF panel including total, oligomeric, and phosphorylated α‐synuclein and Alzheimer's disease biomarkers. Measures of disease severity included disease duration, UPDRS‐III, Hoehn & Yahr stage, and MMSE. Results: After correcting for age, CSF neurofilament levels were 42% higher in PD patients compared with controls ( P < 0.01), whereas serum neurofilament levels were 37% higher ( P = 0.08). Combining CSF neurofilament, phosphorylated‐/total α‐synuclein, and oligomeric‐/total α‐synuclein yielded the best‐fitting model for discriminating PD patients from controls (area under the curve 0.92). The discriminatory potential of serum neurofilament in the CSF biomarker panel was similar (area under the curve 0.90). Higher serum neurofilament was associated with a lower MMSE score. There were no other associations between CSF and/or serum neurofilament levels and clinical disease severity. Conclusions: CSF neurofilament contributes to a panel of CSF α‐synuclein species in differentiating PD patients from healthy controls. Serum neurofilament may have added value to a biofluid biomarker panel for differentiating PD patients from controls. © 2019 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.